FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmacy, namely an antituberculous composition. The pharmaceutical composition contains sodium salt of para-aminosalicylic acid, zinc sulphate, lactose, polyvinylpyrrolidone, citric acid, stearic acid salt, carboxymethyl sodium starch, colloidal silicon dioxide and polyethylene glycol.
EFFECT: composition is characterised by high therapeutic activity, satisfactory technical characteristics and shelf life 2 years and more.
11 cl, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL ANTI-TUBERCULOSIS COMBINED COMPOSITION | 2009 |
|
RU2424808C2 |
COMBINED ANTITUBERCULOUS COMPOSITION | 2009 |
|
RU2413517C1 |
COMBINED ANTITUBERCULOUS COMPOSITION | 2010 |
|
RU2468802C2 |
ANTITUBERCULOUS DRUG AND METHOD OF TREATING | 2010 |
|
RU2449797C1 |
PHARMACEUTICAL COMPOSITION WITH ANTI-TUBERSULOSIS ACTION | 2009 |
|
RU2420288C1 |
ANTITUBERCULAR PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2248797C1 |
PHARMACEUTICAL ANTI-TUBERCULOSIS COMBINED COMPOSITION | 2011 |
|
RU2478389C2 |
COMBINED ANTITUBERCULOUS PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2417087C2 |
COMBINED ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION | 2009 |
|
RU2422145C2 |
MEDICINE FOR TREATING TUBERCULOSIS | 2009 |
|
RU2487702C2 |
Authors
Dates
2011-12-20—Published
2010-07-05—Filed